[Source: https://seekingalpha.com/news/3324858-biondvax-readies-late-stage-study-europe-flu-vaccine-mminus-001]

By    | January 24, 2018

BiondVax Pharmaceuticals (NASDAQ:BVXVsigns a letter-of-intent(LOI) with a European contract research organization aimed at conducting a Phase 3 study there assessing universal flu vaccine M-001 prior to the 2018/2019 flu season.

The LOI includes a €200K upfront fee to cover startup expenses. The parties will ink a master service agreement as soon as feasible.